What does the clinical trial data actually say about finasteride and erectile dysfunction?
The FDA-approved prescribing information for finasteride 1 mg is the starting point for any honest discussion. The registration trials — large, randomized, placebo-controlled studies that enrolled more than 1,500 men — reported the following sexual adverse effects:
- Erectile dysfunction: reported in approximately 1.3% of men on finasteride versus 0.7% on placebo.
- Decreased libido: approximately 1.8% on finasteride versus 1.3% on placebo.
- Ejaculation disorder: approximately 1.2% on finasteride versus 0.7% on placebo.
These numbers convey two important things simultaneously: the risk is real (finasteride exceeds placebo in sexual side effects) and the absolute incidence is low (more than 95% of men in the trials did not report erectile dysfunction on finasteride 1 mg).
The trials also reported that in the subset of men who experienced sexual adverse effects and stopped finasteride, resolution occurred in the majority of cases. However, the trials were not designed to study the long-term trajectory of side effects after discontinuation with rigorous methodology.
The data say two things at once: finasteride raises the risk of erectile dysfunction above placebo, yet more than 95% of men report none.
Why might finasteride affect erectile function? Proposed mechanisms
Finasteride works by inhibiting 5-alpha reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT). DHT is not only relevant to hair follicles — it has broader roles in male physiology, including in the central and peripheral nervous system, penile smooth muscle, and neurosteroid pathways. Several mechanisms have been proposed to explain why DHT suppression might affect erectile function in some men:
Neurosteroid pathways
5-alpha reductase converts progesterone and other precursors into neuroactive steroids including allopregnanolone, a positive allosteric modulator of GABA-A receptors. Finasteride reduces neurosteroid levels, which may affect mood, anxiety, and central regulation of sexual function in susceptible individuals. This pathway is hypothesized as a contributor to both sexual side effects and mood-related reports.
DHT and penile smooth muscle
DHT plays a role in maintaining penile smooth muscle tone and the tissue environment relevant to erectile response. Research in androgen-deprived models has suggested that reducing androgenic signaling can affect the tissue biology of the corpus cavernosum. Whether the degree of DHT reduction produced by finasteride 1 mg is sufficient to produce this effect clinically in most men is debated.
Nocebo effect
The nocebo effect — adverse effects arising from negative expectations rather than pharmacological mechanism — is a legitimate consideration in finasteride research. Studies that have informed patients about potential sexual side effects before prescribing have reported higher rates than studies that did not. This does not mean all finasteride sexual side effects are nocebo; it means the measurement is confounded and absolute incidence figures should be interpreted with this in mind.
Post-finasteride syndrome: what do we know and not know?
A subset of men has reported persistent sexual, cognitive, and mood symptoms that continue after discontinuing finasteride — a collection of reported effects referred to as post-finasteride syndrome (PFS). The FDA added a label update in 2012 acknowledging reports of persistent sexual adverse effects in some men after stopping finasteride.
PFS remains controversial in the medical literature in terms of mechanism, prevalence, and causal attribution. Several research groups have documented case series and surveys of men reporting persistent effects. Proposed mechanisms include epigenetic changes, neurosteroid disruption, and androgen receptor alterations. None is definitively established.
What is established: a subset of men do report persistent symptoms. The proportion of users who experience this is uncertain and subject to methodological debate. Dismissing the phenomenon entirely is not supported by the available case evidence; overstating its prevalence is also not supported by epidemiological data.
This uncertainty reinforces why an informed consent conversation with a clinician before starting finasteride is appropriate — not to discourage use, but to ensure the patient understands both the benefit profile and the risk profile before making a decision.
Who may be more susceptible? Risk factors to discuss
While no validated clinical predictor identifies who will experience finasteride-related sexual side effects before starting treatment, several factors are discussed in the literature as potentially relevant:
- Pre-existing erectile dysfunction or sexual dysfunction: Men with baseline sexual function concerns may be more sensitive to any perturbation.
- History of depression or anxiety: Given the proposed neurosteroid mechanisms, men with mood disorders warrant additional discussion before starting.
- Younger age: Some research has suggested younger men may report higher rates of sexual side effects, though this finding is not universal across studies.
These are not contraindications — they are considerations for the risk-benefit discussion a clinician should have with each patient.
What should you do if finasteride is causing erectile dysfunction?
If you develop erectile dysfunction while taking finasteride, report it to your prescribing clinician. Do not quietly discontinue a prescription medication; abrupt changes in prescription regimens should happen under medical guidance. The clinician can assess whether:
- The symptom is likely finasteride-related or has another cause
- Dose reduction is appropriate
- Discontinuation is indicated
- A different hair loss treatment better fits your risk profile
- An ED evaluation or treatment is warranted
For men who want to continue hair loss treatment but are concerned about finasteride’s sexual side effect profile, topical minoxidil is a prescription-free alternative (OTC in topical form) that does not carry the DHT-suppression mechanism and its associated risks. Oral minoxidil, prescribed off-label at low doses, is another option. Neither is a direct substitute for finasteride in terms of mechanism, but either may be appropriate depending on individual circumstances.
Frequently asked questions
Does finasteride cause erectile dysfunction?
The pivotal clinical trials reported erectile dysfunction in a small percentage of men on finasteride 1 mg (approximately 1.3% vs 0.7% on placebo). This is a real but low-frequency adverse effect. Most cases in trials resolved after stopping the medication. The risk is higher than placebo but not commonly encountered.
How common are sexual side effects with finasteride?
The registration trials for finasteride 1 mg reported sexual adverse effects — including decreased libido, erectile dysfunction, and reduced ejaculate volume — in roughly 3.8% of men on finasteride versus 2.1% on placebo. Observational data from real-world use suggests rates may vary by reporting method and follow-up duration.
Do finasteride side effects go away if I stop taking it?
In the registration trials, reported sexual side effects resolved upon discontinuation in the majority of patients. However, a subset of men has reported persistent sexual side effects after stopping finasteride — a phenomenon referred to as post-finasteride syndrome (PFS). The prevalence of persistent effects remains under study.
Can I take ED medication while on finasteride?
PDE5 inhibitors (sildenafil, tadalafil) are mechanistically distinct from finasteride and are not contraindicated together. However, this is a clinical decision — a prescribing clinician should be aware of all medications you are taking. If you develop erectile dysfunction while on finasteride, discussing it with your clinician is the appropriate first step.
What should I do if finasteride is causing sexual side effects?
Report the side effects to your prescribing clinician promptly. Options include monitoring while continuing if the effect is mild and temporary, dose reduction, switching to a different hair loss treatment, or discontinuing finasteride. Do not stop a prescription medication without consulting the prescribing clinician, but do not stay on a drug that is significantly affecting quality of life without raising it.
Is there a hair loss treatment that does not cause ED?
Topical minoxidil does not have finasteride's DHT-suppression mechanism and does not carry the same sexual side effect profile. It is FDA-approved for hair loss and is a reasonable alternative or addition for patients concerned about sexual side effects. Low-level laser therapy is another option without systemic hormonal effects.